Rep. Byron Donalds Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Representative Byron Donalds (R-Florida) recently sold shares of Regeneron Pharmaceuticals, Inc. NASDAQ: REGN. In a filing disclosed on May 24th, the Representative disclosed that they had sold between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on April 10th. The trade occurred in the Representative's "MORAN WEALTH IRA" account.

Representative Byron Donalds also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Visa NYSE: V on 4/10/2025.
• Sold $1,001 - $15,000 in shares of NU NYSE: NU on 4/10/2025.
• Purchased $1,001 - $15,000 in shares of Amphenol NYSE: APH on 4/10/2025.
• Sold $1,001 - $15,000 in shares of Equifax NYSE: EFX on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Chipotle Mexican Grill NYSE: CMG on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Gartner NYSE: IT on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 3/20/2025.
• Sold $1,001 - $15,000 in shares of Robinhood Markets NASDAQ: HOOD on 3/20/2025.
• Purchased $1,001 - $15,000 in shares of Arista Networks NYSE: ANET on 3/20/2025.
• Sold $1,001 - $15,000 in shares of GoDaddy NYSE: GDDY on 3/20/2025.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $13.54 on Thursday, hitting $605.39. The company had a trading volume of 756,649 shares, compared to its average volume of 806,002. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The stock has a market cap of $65.36 billion, a price-to-earnings ratio of 15.81, a P/E/G ratio of 2.34 and a beta of 0.43. The stock's 50-day simple moving average is $588.18 and its 200 day simple moving average is $671.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue was down 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $9.55 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.58%. Regeneron Pharmaceuticals's payout ratio is 8.96%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. UBS Group dropped their price target on shares of Regeneron Pharmaceuticals from $768.00 to $633.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Robert W. Baird lowered their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Finally, Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $890.60.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Pinney & Scofield Inc. acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $25,000. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Finally, Activest Wealth Management boosted its stake in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 21 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida's 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida's 19th Congressional District. He declared candidacy for the 2026 election. Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor's degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.